TransMedics Group, Inc. — Director's Dealing 2022

Nov 9, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TransMedics Group, Inc. (TMDX)
CIK: 0001756262
Period of Report: 2022-11-07

Reporting Person: Khayal Tamer I (Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-11-07	Common Stock	M	3044	$2.21	Acquired	4344	Direct
2022-11-07	Common Stock	S	3044	$60.04	Disposed	1300	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-11-07	Stock Option (Right to Buy)	$2.21	M	3044	Disposed	2027-06-22	Common Stock (3044)	Direct

Footnotes

F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan.

F2: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $60.00 to $60.36, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3: The option is fully vested.